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e under thebstract Facing the availability of the new generation of quadrivalent meningo-
coccal conjugate vaccines (Menveo, Menactra and others pending for license)
and their recent implementation in Saudi Arabia, experts from 11 countries of the
Middle East region met at a ‘‘Meningococcal Leadership Forum’’ (MLF), which took
place in May 2010 in Dubai. The participants of the conference discussed the impor-
tance of introducing the concept of conjugate vaccines – especially for children and
adolescents – and elaborated a consensus recommendation to support healthcare
professionals and decision makers with their expertise. In experts opinion, conju-
gate vaccines are the best choice for the prevention of meningococcal disease
caused by serogroups A, C, W-135 and Y. As quadrivalent meningococcal conjugate
vaccines are registered and available in the Middle East region, they should replace
plain polysaccharide vaccines and be integrated in pediatric and adolescent vaccina-
tion schedules, including infant vaccination concomitantly with basic EPI vaccines
when licensed.
ª 2012 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).2
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1.1. Pathogen and transmission
Worldwide, most cases of meningococcal diseases
are caused by 5 of 12 known serogroups (A, B, C,
W-135, Y) of Neisseria meningitidis, which is trans-
mitted from human to human by respiratoryabia. Published by Elsevier Ltd.
creativecommons.org/licenses/by-nc-nd/4.0/).
24 A. Shibl et al.secretion or direct contact and colonizing the naso-
pharynx. Asymptomatic carriage is common in the
general population and can be as high as 35% [1],
during Hajj it can reach up to 86% [2]. Rather few
carriers become symptomatic, when the bacteria
penetrate the barrier of nasopharyngeal mucosa
and get into blood circulation and/or the brain,
causing septicemia and/or meningitis. There are
several risk factors associated with bacterial car-
riage, including: (i) crowded conditions (e.g. mili-
tary barracks, dormitories, pubs, events); (ii)
travels to endemic areas; and (iii) personal behav-
iors (e.g. kissing, coughing, smoking), all of which
increase exposure to the bacteria [1]. Most if not
all these risk factors apply to adolescents, who are
the biggest global reservoir for N. meningitidis of
all age groups and thus the key for transmission [3].
N. meningitidis is a very diverse, genetically
unstable bacterial pathogen that changes genomic
information and can change in itself through vari-
ous mechanisms (e.g. mutation, horizontal gene
transfer, recombination) to survive selective pres-
sures like immune responses or antibiotics [4]. Cap-
sular switch is a well-known example for the
biodiversity of meningococci and was the cause of
the emergence of serogroup W-135, which is re-
garded to have originated from a virulent sero-
group C strain [5]. The capsular polysaccharides
on the bacterias cell surface are the prerequisite
for its pathogenicity and escape mechanism against
the bodys defenses and thus the target of vaccines
(except for serogroup B vaccines).
1.2. Burden of disease
N. meningitidis remains the primary cause of bac-
terial meningitis and septicemia that have not yet
been fully controlled by conjugate vaccines, as it
was achieved for Haemophilus influenzae type b
(Hib) [6] and pneumococcal disease [7]. While
some countries (e.g. the United Kingdom) have
made significant progress by introducing meningo-
coccal serogroup C conjugate vaccines, this only
covered disease caused by serogroup C and did
not affect other serogroups. The potentially life-
threatening meningococcal disease occurs sud-
denly in otherwise healthy persons and the progres-
sion can be very rapid and unpredictable [8]. Due
to the nonspecific, flu-like symptoms in the early
stage, meningococcal disease is difficult to diag-
nose and accurate treatment may be delayed [9].
Signs may be subtle even in far-advanced stage
and can be misdiagnosed. Therefore the time
frame for appropriate treatment is very tight:
The mean hospital admission time is 19 h after
the onset of first symptoms, but a critical situationor death can already occur within 24 h [9]. Even
with appropriate treatment and intensive care,
the case-fatality rate (CFR) is high: 10–30%
depending on manifestation, age (CFR increases
with age) and serogroup (W-135 and Y are associ-
ated with higher CFR than B and C) [10–12]. Up
to 20% of survivors suffer from permanent severe
sequelae such as hearing loss, skin necrosis, sei-
zures or limb amputation [10]. In most countries
meningococcal disease shows a bimodal age distri-
bution with the highest burden in infants and tod-
dlers (0–4 years of age) followed by a second
peak in adolescents and young adults (15–24 years
of age). Compared to infants, meningococcal dis-
ease is more severe and CFR is higher in adoles-
cents [8]. Besides the individual burden of the
patients and their families, also the societal impact
and the healthcare costs are substantial. For all
these reasons, prevention of meningococcal dis-
ease plays an important role – currently four sero-
groups can be covered by the vaccination: A, C, W-
135 and Y (with the exception of New Zealand and
Cuba, where specific OMV-vaccines are used to
cover specific endemic B-strains).
1.3. Changing epidemiology
Both incidences of disease and distribution of sero-
groups are continually changing. Long-term data
show various incidences of meningococcal disease
with a cyclic change over time that is also observed
in Saudi Arabia and in the countries of the African
meningitis belt, where the peaks are almost equal
in the neighboring countries (‘‘synchrony’’) [13].
All five major serogroups exist everywhere at the
same time, but the relative proportions highly vary
from country to country and are changing unpre-
dictably. There are numerous examples for the dy-
namic change in serogroup distribution, e.g. in the
United States [14] and Colombia [15], serogroup Y
increased significantly in the last decade, whereas
Canada [16], Brazil [17] and the Czech Republic
[18] reported a shift to serogroup C in that period.
In Saudi Arabia [19] W-135 gained dominance with-
in only 2 years followed by other countries also
observing much higher proportions of W-135 (e.g.
Turkey, South Africa, Nigeria, and Argentina) [20].
Besides the genetic variability of bacteria, tra-
vel is one of the major drivers influencing the
change of epidemiology. International travel can
promote and accelerate the spread of different
serogroups all over the world (especially after mass
gatherings like the Hajj), which can lead to global
outbreaks as well as to the unexpected establish-
ment of a prior non-endemic serogroup, as docu-
mented e.g. for A and W-135. The global spread
Meningococcal disease prevention consensus 25of serogroup A was the effect of three great pan-
demics in Asia during the last century; recent out-
breaks are reported from India and the Philippines
[21]. In 2000 and 2001, serogroup W-135 was trans-
ferred from Hajj to other countries all over the
world and caused secondary infections in the home
countries of pilgrims [19]. A comparison of the two
outbreaks in Saudi Arabia in 2000 and 2001 shows a
large spread of disease outside the holy cities and
an increase of cases in young children (<5 years of
age) [22]. This clearly proves that the use of poly-
saccharide vaccines after the first outbreak could
not significantly reduce carriage and therefore
could not prevent transmission and infection in
the unvaccinated—unlike the experiences with con-
jugate vaccines in general have shown.
The changing epidemiology is an important pub-
lic health challenge and requires networking and
surveillance at the global, national and district lev-
els for decision-making of comprehensive interven-
tion methods. The cyclic nature of meningococcal
disease, the unpredictable change of serogroup
distribution and increasing travel underscore the
need for a prevention strategy that incorporates
all major serogroups. Long-term protection with
conjugate vaccines against as many serogroups as
possible and among as many age groups as possible
would be the optimal solution.
1.4. Polysaccharide vs. conjugate vaccines
Nowadays, plain meningococcal polysaccharide
vaccines are considered to be outdated because
of important limitations (Table 1): they are not
immunogenic in young children (<2 years of age),
who have the greatest burden of disease; they do
not elicit an immune memory and provide only lim-
ited duration of protection (3 years); they have
no significant impact on carriage and transmission
(no herd immunity); and they cannot be boosted.
Repeated polysaccharide vaccinations result in re-
duced immune responses (hyporesponsiveness)
[5]. Most of these disadvantages are based on the
lack of T-cell activation by plain polysaccharides.Table 1 Comparison of plain polysaccharide versus conjugate
Vaccine characteristics Pol
Effective in infants No
Immune memory No
Prolonged duration of protection No
Booster effect No
Reduction of carriage No
Contribution to herd effect No
Hyporesponsiveness with repeated doses yes
Harrison LH, Prospects for vaccine prevention of meningococcal inThe technology of meningococcal conjugate vac-
cines may overcome these limitations. As a result of
a carrier protein to which the capsular polysaccha-
rides are chemically linked (conjugated), a T-cell
mediated immune response with all its benefits is in-
duced: Much more and, above all, functional anti-
bodies are produced (high immunogenicity even in
infants aged >2 months) and an immune memory is
induced (prolonged duration of protection), effec-
tive boosting (no hyporesponsiveness) and preven-
tion/clearance of carriage can be achieved [5].
The latter is of fundamental importance to prevent
further transmission of bacteria for contributing to
the herd immunity, as demonstrated over the years
by the widespread use of Hib and pneumococcal
conjugate vaccines, as well as in some countries
with meningococcal C conjugate vaccines.
1.5. Success of meningococcal C conjugate
vaccines
The development of conjugate vaccines has
brought considerable immunologic improvements
over plain polysaccharide vaccines [5]. During the
1990s a dramatic and rapid increase of severe
meningococcal C cases and a serogroup shift to
hypervirulent C strains was observed in European
countries, as well as in Canada, where the inci-
dence of C cases was tripling at that time. When
the new generation of meningococcal C conjugate
vaccines became available, immunization pro-
grams were implemented in several countries. In
the United Kingdom a national vaccination program
started in 1999 with two parallel approaches:
meningococcal C conjugate vaccination was in-
cluded in the routine immunization schedule for in-
fants (three doses at 2, 3, and 4 months of age) and
in a catch-up campaign for all children aged 1–
18 years (one single dose). With this strategy high
coverage rates among the age groups most at risk
were achieved within a short period of time. The
data are very well analyzed and show a significant
continuous reduction in serogroup C disease (up
to 97%) as well as an overall reduction in thevaccines.
ysaccharide vaccines Conjugate vaccines
Yes
Yes
Yes
Yes
Yes
Yes
No
fection. Clin Microbiol Rev 2006; 9(1):142–164.
26 A. Shibl et al.incidence of meningococcal disease, even in the
unvaccinated population [23].
Thus, conjugate vaccines not only had a substan-
tial direct impact on vaccinees, but also generated
an impressive indirect effect in unvaccinated
individuals. This herd immunity is createdathigh vac-
cinationcoverageby the significant reductionof sero-
group C carriage (81%) that ceases transmission
[24]. The impact of conjugate vaccination on the car-
riage is also reflected in the serogroupdistribution, as
in the UK for which the percentage of serogroup C de-
creased significantly [24]. As expected, there was no
impact on other serogroups (neither on carriage nor
on actual cases of invasive meningococcal disease),
because no cross-protection between the immuno-
logically different meningococcal serogroups exists.
Importantly, until today,no replacement isobserved,
i.e. the ecological niche in the throat is not replaced
by other serogroups ofmeningococci. Similar success
documenting that meningococcal C conjugate vac-
cines are veryeffective tools for adramatic reduction
of meningococcal disease and death was achieved in
the Netherlands, Belgium, Iceland, Ireland, Spain,
Portugal and Canada.1.6. Conjugate technology and carrier
proteins
The capsular polysaccharides (sugar chains) of
meningococcal serogroups differ biochemically
and thus immunologically. Therefore a specific im-
mune response against A, C, W-135 and Y is re-
quired, respectively, and no cross-reaction
between antibodies directed to one serogroup
against another is possible. The biochemistry (for-
mulation) of a vaccine helps to identify its essence
and is the prerequisite for good clinical efficacy.
Many factors of the complex technology of a conju-
gate vaccine can have an impact on immunogenic-
ity (and tolerability), in particular the length and
homogenicity of the sugar chains, the nature of
the carrier protein and the method of linkage in be-
tween (direct or indirect conjugation via a linker).
The following carrier proteins are used for the
conjugation of polysaccharides by different
manufacturers:
• Hib vaccines: CRM197 (Corynebacterium diphtheriae
cross-reactivematerial), diphtheria toxoid (D), tetanus
toxoid (T), OMPC (outer membrane protein complex).
• Pneumococcal vaccines: CRM197, Protein D from H.
influenzae, T (in development).
• Meningococcal C vaccines: CRM197, T (also Hib/MenC
combination).
• Meningococcal ACWY vaccines: CRM197, D, T (in
development).For the first quadrivalent meningococcal conju-
gate vaccine (Menactra) D is used as carrier
protein, the other recently developed ACWY conju-
gate vaccine (Menveo) contains CRM197. One fur-
ther quadrivalent conjugate vaccine using T as
carrier protein is currently under clinical investiga-
tion. D, T and CRM197 have a long history in human
use and are well known to induce a robust immune
response in a broad range of age groups (including
infants) as well as for their proven safety profile.
Whereas D and T have to be detoxified with form-
aldehyde, CRM197 is a natural non-toxic mutant of
D and therefore needs no chemical inactivation.
(For details of conjugation technology see Bro¨ker
et al. [25] and Ravenscoft [26].)
N. meningitidis is the only bacterium that can
generate widespread outbreaks and epidemics of
meningitis [27]. Most cases of invasive meningococ-
cal disease occur in infants and young children. Due
to the high morbidity and mortality and the chang-
ing epidemiology, vaccination as broad as possible
in the serogroup coverage and in the age group cov-
erage is recommended for the prevention of
meningococcal infections. Until now meningococ-
cal polysaccharide vaccines are widely used in the
Middle East, present day quadrivalent conjugate
vaccines are available that provide superior advan-
tages (see Table 1).1.7. Waning immunity
Experience with the large scale immunization pro-
gram in the UK using monovalent meningococcal C
conjugate vaccine showed that infants primed with
MenC conjugate vaccines needed a booster dose to
provide persistently protective antibody levels la-
ter in life [28]. Since meningococcal disease can
progress more rapidly than the time for reactiva-
tion of immune memory to take place, the persis-
tence of circulating bactericidal antibodies at a
protective level is necessary for clinical protection
[29]. Consequently the schedule of 2, 3, 4 months
of age was changed to 2, 4, 12 months to induce
longer persistence of circulating antibodies by the
booster dose. However, the great success of the
campaign achieving the herd immunity was mainly
accomplished by the catch-up campaign in adoles-
cents. Due to waning immunity and in the absence
of an adolescent booster, the herd immunity is
likely to diminish over the coming years. Based on
the UK experience, the introduction of a routine
adolescent booster dose is being discussed in
several countries. Some countries have started to
introduce an adolescent booster, (e.g. Canada,
Switzerland), Austria is the first country to
Meningococcal disease prevention consensus 27recommend an adolescent booster explicitly with
quadrivalent Men ACWY conjugate vaccine follow-
ing primary immunization with monovalent Men C
vaccine.
2. Pediatric consensus-recommendation
for meningococcal ACWY conjugate
vaccination
2.1. Prevention in adolescents
As described in part 1 of this paper, adolescents have
the highest carriage rate and are the largest global
reservoir for N. meningitidis of all age groups (key
for transmission). Consequently, they are at high
risk for contracting meningococcal disease (2nd
peak of incidence after infants/toddlers), mainly
because of their social behavior and individual life-
style [30]. Compared with infants, meningococcal
disease is more severe in adolescents and case fatal-
ity rate is higher [31,32]. In addition, it has been ob-
served, that hypervirulent strains tend to circulate
preferably in adolescents, and especially during epi-
demics, the peak in adolescence is very high [33].
It is very important to reduce the carrier rate in
the teenage group, as targeting the adolescents
will also indirectly protect infants and potentially
boost the waning immunity. Vaccinating this age
group will both enhance the immune response
and will have optimal effect on carriage. The need
for high vaccine coverage rates remains the most
important challenge: Health issues in general, and
vaccinations in particular, are not considered a pri-
ority of teenagers, and vaccination campaigns in
this age group may need new approaches. The most
successful approach to catch adolescents and
young adults would be with school campaigns and
within the military establishment.
Also from a societal perspective, the ability to
prevent morbidity and mortality in a segment of
population that is critical for a nations future (be-
cause adolescent health is critical to social produc-
tivity) creates an imperative to have adolescent
vaccination as a cornerstone of the public health
policy. Notably, because vaccinating adolescents
leads to a higher persistence of seroprotective
antibodies, the public health investment will be
more durable [34,35].
2.2. Vaccination practices in the
Middle East region
In many countries of the Middle East region menin-
gococcal polysaccharide vaccines are given rou-
tinely to children above 2 years of age or toschoolchildren or selectively to risk groups like
pilgrims, soldiers, healthcare workers and travel-
ers. Many of these vaccinees get immunized every
3 years or even more frequently. Thus hyporespon-
siveness is an important issue in this region.
An unmet medical need is the protection of in-
fants and toddlers below 2 years of age, because
polysaccharide vaccines are not efficacious in this
most vulnerable age group with the highest inci-
dence of meningococcal disease. Conjugate menin-
gococcal ACWY vaccines can overcome these
limitations and will be the optimal protection
strategy for all age groups. Saudi Arabia decided
to convert to ACWY conjugate vaccines in 2010
[36], starting to target all people involved in pil-
grimage, and is working on an adolescent immuni-
zation program with meningococcal vaccination
as an integral part of it.
2.3. Consensual recommendation for
meningococcal ACWY conjugate vaccination
The experts of the Middle East region agree on the
concept of using conjugate vaccines replacing poly-
saccharide vaccines. Conjugate vaccines are re-
garded as the best choice for the prevention of
meningococcal disease caused by serogroups A, C,
W135 and Y. The potential benefits of meningococ-
cal conjugate vaccines include longer duration of
protection, reduction of carriage, contribution to
the herd immunity without hyporesponsiveness
upon repeated doses, and giving a good sero-re-
sponse in subjects previously vaccinated with re-
peated doses of the polysaccharide vaccines (i.e.
overcoming the hyporesponsiveness induced by
polysaccharide vaccines) [37]. Their potential to
reduce transmission by prevention/clearance of
carriage offers the possibility to prevent dissemina-
tion of the bacteria. Many countries have
experienced the occurrence of meningococcal
infections despite high coverage of polysaccharide
vaccinations. Therefore, the impact of conjugate
vaccines on carriage is of major interest from an
epidemiologic, economic and also from a public
health perspective. Each single case of meningo-
coccal disease, no matter if imported or indige-
nous, requires a public health response (i.e.
identification of close contacts for chemoprophy-
laxis). Another important advantage is the chance
of reducing the ‘‘overuse’’ of antibiotics: upon
large scale and widespread use of conjugate vac-
cines, there will be no more – or at least much less
– need for chemoprophylaxis. A remaining con-
cern, however, is that conjugate ACWY vaccines
do not cover all serogroups (B, X).
28 A. Shibl et al.2.4. How to integrate tetravalent conjugate
vaccines in pediatric and adolescent
settings?
• Step1: Adolescents and young adults (the major age
cohort of carriage) should be vaccinated as soon as
possible – ideally together with other important vacci-
nations at this age (for example TdaP booster, Rubella,
HPV; depending on each countrys adolescent vaccina-
tion program, which is not uniform in the countries of
the region). With implementation in schools/at mili-
tary, this target group can be reached more easily.
• Step 2: For infants and toddlers (above 2 months to
below 2 years of age) ACWY conjugate vaccination
should be part of the national immunization program
and be integrated into the routine schedules upon
licensure in the respective age. As the majority of
invasive meningococcal disease occurs in early
infancy, the ideal timeframe would be concomitant
administration with basic EPI vaccines, depending on
national immunization schedules of individual coun-
tries, for instance at the 2,4,and 6 months-schedule.2.5. Which implementation strategy
is recommended?
• The optimal strategy is to carry out a mass immuniza-
tion campaign of all adolescents (11 years and above)
at the same time, followed by regular adolescent
cohort vaccinations (at the age of 11 years or above,
potentially when Td booster doses are scheduled,
according to national policies).
• Infant and toddler vaccinations should be implemented
when licensed. Preferred age would be early infancy.
As early as available, quadrivalent meningococ-
cal conjugate vaccines should be preferred over
polysaccharide vaccines. At present, the use of
ACWY conjugate vaccines is limited to the regis-
tered age (2 years without upper age limit for Men-
veo, 9 months to 55 years for Menactra. Both
vaccines are registered and are available in the Mid-
dle East region, including Saudi Arabia. For some
countries, the costs of conjugate vaccines may be
a financial burden at introduction, but costs will
be recovered within some years through long-term
protection and the added value of the herd immu-
nity. The concept of conjugate vaccines is convinc-
ing and offers the opportunity to significantly
reduce the burden of meningococcal disease in all
age groups.
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